Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
Gene-Environment Interactions01:20

Gene-Environment Interactions

Gene expression is a dynamic process that is significantly influenced by environmental factors. This interaction underlies the complex nature of biological development and the phenotypic differences observed among individuals, even among those with identical genetic makeups. Factors such as radiation, temperature, behavior, nutrition, and stress play pivotal roles in determining how genes are expressed. The concept of the reaction range is central to understanding this interaction. It posits...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ECETOC TRAv3: An In-depth Comparison of Publicly Available Measurement Data Sets With Modelled Estimates of Occupational Inhalation Exposure to Chemicals.

Annals of work exposures and health·2023
Same author

An assessment of the ECETOC TRA Consumer tool performance as a screening level tool.

Journal of exposure science & environmental epidemiology·2023
Same author

The ECETOC-Targeted Risk Assessment Tool for Worker Exposure Estimation in REACH Registration Dossiers of Chemical Substances-Current Developments.

International journal of environmental research and public health·2020
Same author

Solvent Transfer-Efficiency of Risk Management Measures.

Annals of work exposures and health·2017
Same author

Improving the relevance and efficiency of human exposure assessments within the process of regulatory risk assessment.

Environmental science. Processes & impacts·2017
Same author

Assessment of the potential human health risks from exposure to complex substances in accordance with REACH requirements. "White spirit" as a case study.

Regulatory toxicology and pharmacology : RTP·2017

Related Experiment Video

Updated: Jun 2, 2026

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Generic exposure scenarios: their development, application, and interpretation under REACH.

Chris Money1, Alison Margary, Dook Noij

  • 1ExxonMobil Petroleum and Chemical, Machelen, Belgium. chris.money@exxonmobil.com

The Annals of Occupational Hygiene
|May 10, 2011
PubMed
Summary

Manufacturers and importers (M/Is) must communicate safe chemical use via exposure scenarios (ES) under the European Union Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) Regulation. The European solvents industry developed generic exposure scenarios for clearer communication and compliance.

More Related Videos

Effective Analysis of Human Exposure Conditions with Body-worn Dosimeters in the 2.4 GHz Band
06:43

Effective Analysis of Human Exposure Conditions with Body-worn Dosimeters in the 2.4 GHz Band

Published on: May 2, 2018

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

Related Experiment Videos

Last Updated: Jun 2, 2026

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Effective Analysis of Human Exposure Conditions with Body-worn Dosimeters in the 2.4 GHz Band
06:43

Effective Analysis of Human Exposure Conditions with Body-worn Dosimeters in the 2.4 GHz Band

Published on: May 2, 2018

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

Area of Science:

  • Chemical safety and regulatory compliance
  • Environmental health and safety
  • Industrial chemistry

Background:

  • The European Union Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) Regulation imposes new obligations on chemical manufacturers/importers (M/Is) and downstream users (DUs).
  • M/Is must communicate safe chemical usage through exposure scenarios (ES) annexed to extended safety data sheets.
  • Downstream users (DUs) are obligated to implement the control measures specified in the exposure scenarios.

Purpose of the Study:

  • To ensure REACH communications are understandable, consistent, and meet regulatory requirements.
  • To develop a standardized approach for communicating safe chemical use within the European solvents industry.
  • To provide publicly available generic exposure scenarios for M/Is and DUs.

Main Methods:

  • Development of generic approaches for describing common solvent uses.
  • Collaboration with downstream user groups to ensure relevance and clarity.
  • Integration of these approaches into REACH registrations and safety data sheet communications.

Main Results:

  • The European solvents industry has developed and validated 'generic exposure scenarios' (GES).
  • These GES provide a standardized method for communicating safe solvent use.
  • The utility of GES is recognized under REACH, making them publicly available.

Conclusions:

  • Generic exposure scenarios offer a practical solution for meeting REACH communication requirements.
  • These scenarios enhance clarity and consistency in chemical safety information for downstream users.
  • The adoption of GES facilitates compliance and promotes safer chemical handling across supply chains.